Form 4: Adicet Bio CEO Granted 468,555 Stock Options

Adicet Bio's President & CEO, Schor Chen, was granted 468,555 stock options with a $6.81 exercise price, vesting monthly over four years.

Summary

• Schor Chen, President & CEO and Director of Adicet Bio, Inc. (ACET), acquired 468,555 stock options.
• The stock options have an exercise price of $6.81 per share.
• The grant date for these options was March 25, 2026.
• The options will expire on March 24, 2036.
• Vesting occurs monthly, with 1/48th of the shares vesting on each of the next forty-eight monthly anniversaries of the grant date.
• Vesting is contingent upon Schor Chen maintaining a service relationship with Adicet Bio, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a routine compensation disclosure, it signifies continued executive commitment and aligns management incentives with long-term shareholder value, which is generally favorable.

Positives

• The grant of stock options aligns the interests of the President & CEO with those of shareholders, as the value of the options is tied to the company's stock performance.
• The long-term vesting schedule (48 months) encourages sustained leadership and commitment from the CEO.

Future Outlook

The vesting schedule, which extends over 48 months, indicates an expectation of continued service from the President & CEO, Schor Chen, for the foreseeable future to fully realize the benefit of the options.

Industry Context

StockSavvy.ai notes that the grant of stock options to executive leadership is a common practice in the biotechnology and broader corporate sectors. This form of compensation is designed to incentivize long-term performance and align management's financial interests with shareholder value creation, particularly in industries with long development cycles and high R&D costs like biotech.

Comparison to Industry Standards

• Executive stock option grants with multi-year vesting schedules are a standard component of compensation packages across many industries, including biotechnology.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development within the biotech sector to ensure competitive and performance-driven compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CEO's financial incentives with shareholder returns, potentially leading to more focused efforts on increasing stock value.
• Employees: May signal stability in leadership, potentially impacting employee morale and retention.

Next Steps

• Schor Chen must maintain a service relationship with Adicet Bio, Inc. for the next 48 months to fully vest the granted stock options.

Key Dates

Keywords

Adicet Bio, ACET, Stock Options, Executive Compensation, Insider Transaction, Schor Chen, Biotechnology, SEC Form 4